13 assets in Prostate Disorder

Therapeutic assets addressing Prostate Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Dinitrogen Monoxide Prostate Disorder	Beth Israel Deaconess Medical Center	P4	BB (69)
Oxygen Prostate Disorder	Beth Israel Deaconess Medical Center	P4	BB (66)
Nivolumab Prostate Disorder	Australian and New Zealand Urogenital and Prostate Cancer Trials Group	P2	B (60)
Olaparib Prostate Disorder	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	B (57)
Flotufolastat F 18 Prostate Disorder	University of Florida	P2	CCC (53)
Ipilimumab Prostate Disorder	Australian and New Zealand Urogenital and Prostate Cancer Trials Group	P2	CCC (53)
Vipivotide Tetraxetan Prostate Disorder	Australian and New Zealand Urogenital and Prostate Cancer Trials Group	P2	CCC (53)
177Lu-rhPSMA-10.1 Prostate Disorder	Blue Earth Therapeutics Ltd	P1/2	CCC (48)
Darolutamide Prostate Disorder	Celcuity Inc	P1/2	CCC (48)
Gedatolisib Prostate Disorder	Celcuity Inc	P1/2	CC (47)
sys6043 Prostate Disorder	Conjupro Biotherapeutics, Inc.	P1	CC (43)
68Ga-HTK03149 Prostate Disorder	British Columbia Cancer Agency	N/A	D (30)
Tamsulosin Prostate Disorder	Menoufia University	N/A	D (30)